SG Americas Securities LLC Has $135,000 Position in CVRx, Inc. (NASDAQ:CVRX)

SG Americas Securities LLC lessened its position in CVRx, Inc. (NASDAQ:CVRX) by 12.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,690 shares of the company’s stock after selling 1,563 shares during the period. SG Americas Securities LLC’s holdings in CVRx were worth $135,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. PDT Partners LLC bought a new position in CVRx in the third quarter valued at approximately $543,000. International Assets Investment Management LLC acquired a new stake in shares of CVRx in the 3rd quarter valued at approximately $338,000. Barclays PLC lifted its stake in CVRx by 312.5% in the 3rd quarter. Barclays PLC now owns 19,067 shares of the company’s stock valued at $169,000 after purchasing an additional 14,445 shares during the last quarter. Jane Street Group LLC raised its position in shares of CVRx by 36.1% in the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock valued at $168,000 after purchasing an additional 5,053 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of CVRx by 2.2% during the third quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock worth $2,600,000 after acquiring an additional 6,443 shares during the period. Institutional investors own 75.27% of the company’s stock.

CVRx Trading Up 1.7 %

Shares of CVRX stock opened at $14.89 on Tuesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 11.32 and a quick ratio of 10.23. CVRx, Inc. has a 1-year low of $6.40 and a 1-year high of $24.55. The stock has a market capitalization of $361.23 million, a PE ratio of -5.54 and a beta of 1.30. The business has a 50-day moving average of $14.67 and a 200 day moving average of $11.85.

CVRx (NASDAQ:CVRX) last posted its earnings results on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative return on equity of 96.36% and a negative net margin of 116.91%. As a group, sell-side analysts anticipate that CVRx, Inc. will post -1.89 earnings per share for the current year.

Analysts Set New Price Targets

CVRX has been the subject of a number of analyst reports. Lake Street Capital boosted their price target on CVRx from $12.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. William Blair raised shares of CVRx from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 14th. Canaccord Genuity Group raised their price target on shares of CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a report on Wednesday, February 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $14.00 target price on shares of CVRx in a report on Wednesday, October 23rd. Finally, Craig Hallum raised their target price on CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, January 17th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $17.83.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.